MedDataX Logo

Effect of Various Treatment Modalities on Dendritic Vial Ulcer

NCT ID: NCT05313828

Last Updated: 2022-04-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-18

Study Completion Date

2022-07-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Eye infection is a prevalent problem in primary care and remains a crucial healthcare concern. According to the American Academy of Ophthalmology (AAO), herpes simplex virus (HSV) keratitis (HSK) is the leading cause of infectious blindness worldwide . HSK is defined as a corneal inflammatory condition caused by the HSV infection . The global incidence of herpetic keratitis is estimated at 1.5 million per year, resulting in 40,000 new cases of severe visual impairment associated with corneal scarring and opacification . HSV type I (HSV-1) is by far the most predominant causative pathogen of eye infections\]. HSV-1 is also known for causing orolabial herpes, HSV folliculitis, herpes gladiatorum, herpetic whitlow, and eczema herpeticum . HSV can be transferred to the eye by touching an active lesion and then the eye. The National Health and Nutrition Evaluation revealed a seroprevalence of HSV-1 in 53.9% of 14-49 year olds, and 90% of adults 50 years or older , indicating that the majority of the population has been exposed to this virus thus are at risk of developing HSK.

In this study we evaluate the efficacy of different treatment modalities on viral keratitis HSK.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Herpetic Eye Disease Study (HEDS) I

NCT00000138

Keratitis, Herpetic Ocular Herpes Simplex
UNKNOWN PHASE3

Role of Amniotic Membrane Extract Eye Drops as an Adjunctive Therapy in Resistant Corneal Ulcers

NCT06909149

Amniotic Membrane Extract Eye Drops Resistant Corneal Ulcers
COMPLETED NA

A Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis

NCT06474442

Herpes Simplex Virus Type I Stromal Keratitis
RECRUITING PHASE2

Non-invasive Diagnostics of Microbial Keratitis

NCT06364878

Infectious Keratitis
RECRUITING

Efficacy of Riboflavin-Enhanced Hyaluronic Acid Eye Drops in Treating Dry Eye Disease

NCT06122428

Dry Eye Disease
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Corneal Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group 1'

patients with viral ulcers will receive antiviral medication with antibiotics

Acyclovir

Intervention Type DRUG

acyclovir 4 times /day

Tobramycin

Intervention Type DRUG

tobramycin 4 times /day

group 2

patients with viral ulcers will receive antiviral medication, tear substitutes with antibiotics

Acyclovir

Intervention Type DRUG

acyclovir 4 times /day

Tobramycin

Intervention Type DRUG

tobramycin 4 times /day

Sodium Hyaluronate

Intervention Type DRUG

Sodium Hyaluronate 4 times/day

group 3

patients with viral ulcers will receive antiviral medication, weak steroids(at the same time) with antibiotics

Acyclovir

Intervention Type DRUG

acyclovir 4 times /day

Tobramycin

Intervention Type DRUG

tobramycin 4 times /day

Fluorometholone

Intervention Type DRUG

Fluorometholone 4 times/ day

group 4

patients with viral ulcers will receive antiviral medication with antibiotics followed by weak steroid after epithelial healing

Acyclovir

Intervention Type DRUG

acyclovir 4 times /day

Tobramycin

Intervention Type DRUG

tobramycin 4 times /day

Fluorometholone

Intervention Type DRUG

Fluorometholone 4 times/ day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acyclovir

acyclovir 4 times /day

Intervention Type DRUG

Tobramycin

tobramycin 4 times /day

Intervention Type DRUG

Fluorometholone

Fluorometholone 4 times/ day

Intervention Type DRUG

Sodium Hyaluronate

Sodium Hyaluronate 4 times/day

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

patients with epithelial viral ulcers

\-

Exclusion Criteria

* patients with stromal keratitis patients with corneal opacity
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sohag University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hany Mahmoud,MD

principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sohag University

Sohag, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hany Mahmoud

Role: CONTACT

[email protected]
00201024368111

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hany Mahmoud

Role: primary

[email protected]
01024368111

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

soh-med-22-02-28

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis
NCT06474416 ACTIVE_NOT_RECRUITING PHASE1
Efficacy of Xiidra in Dry Eye Disease After Collagen Cross Linking
NCT05045053 UNKNOWN PHASE4
0.01% Hypochlorous Acid in the Treatment of Blepharitis
NCT05608980 UNKNOWN NA
CsA vs MMC for Preventing Pterygium Recurrence
NCT06944132 COMPLETED NA
A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease
NCT01733992 COMPLETED PHASE1
The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study
NCT05655689 COMPLETED
Treatment of Corneal Infiltrates Secondary to Epidemic Keratoconjunctivitis
NCT04376970 COMPLETED PHASE4
PMCF Study to Evaluate Performance and Safety of "Hyaluronic Acid (HA)-Based Eyedrops" Used to Relieve Dry Eye Symptoms
NCT05807360 COMPLETED NA
Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye
NCT01240382 COMPLETED PHASE3
Exploratory Study of OPC-12759 Ophthalmic Suspension
NCT01493180 COMPLETED PHASE2
Au-Ag-Cu2O NG With PTT Anti Drug-resistant Microbial Keratitis
NCT05268718 UNKNOWN EARLY_PHASE1
Pack Cross Linking for Infectious Keratitis
NCT05881187 UNKNOWN NA
Change in Ocular Flora Resistance From Repeated Topical Antibiotic Use
NCT01181713 COMPLETED
Potential Role of Ocular Surface Microbiome in Dry Eye: Microbial Interactions and Symptom Alleviation
NCT06936462 COMPLETED NA
Study on Safety and Performance of an Artificial Tear in Dry Eye Treatment in Subjects With Ocular Surface Inflammation
NCT04633863 COMPLETED NA
A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease
NCT04498182 COMPLETED PHASE2
Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
NCT02929823 COMPLETED PHASE2
Evaluation of Performance and Safety of Eye Drops With Hyaluronic Acid 0.30% and 0.15%
NCT06189456 RECRUITING NA
A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye
NCT04633213 UNKNOWN PHASE3
Efficacy of 0.38% and 0.18% Sodium Hyaluronate Ocular Lubricants for Dry Eye in Adult Gazan Participants
NCT06851364 COMPLETED PHASE2
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
NCT01900249 COMPLETED PHASE2
Efficacy of 0.28% Sodium Hyaluronate Eye Drops in Patient with Moderate to Severe Dry Eye
NCT06860659 ENROLLING_BY_INVITATION PHASE4
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
NCT02815293 TERMINATED PHASE3
The Asia Cornea Society Infectious Keratitis Study
NCT01560208 UNKNOWN
The Efficacy of Permethrin 5%, Fusidic Acid 1% and Synthomycine 5% for Demodex - Blepharitis
NCT03105505 UNKNOWN PHASE4